{
  "orphacode": "333",
  "disease_name": "Farber disease",
  "socioeconomic_impact_studies": [
    {
      "cost": 0,
      "measure": "Qualitative clinical burden and severity",
      "label": "Acid ceramidase deficiency: Farber disease and SMA-PME",
      "source": "https://ojrd.biomedcentral.com/articles/10.1186/s13023-018-0845-z",
      "country": "International",
      "year": "2018"
    },
    {
      "cost": 0,
      "measure": "Qualitative disease overview and symptom impact",
      "label": "ASAH1-Related Disorders - Symptoms, Causes, Treatment",
      "source": "https://rarediseases.org/rare-diseases/farbers-disease/",
      "country": "USA",
      "year": "2025"
    }
  ],
  "score": 3,
  "evidence_level": "Low evidence",
  "justification": "No quantitative cost-of-illness studies were identified for Farber disease; the available evidence is limited to qualitative descriptions of severe clinical burden from peer-reviewed and patient-organisation sources.",
  "metadata": {
    "processing_timestamp": "2025-07-18T19:21:15.050718",
    "run_number": 1,
    "orphacode": "333"
  }
}